ライフサイエンスコーパス: hereditary angioedema

1 bant is approved for treatment of attacks of hereditary angioedema.

2 1 inhibitor concentrate in the management of hereditary angioedema.

3 wed interest in the biology and treatment of hereditary angioedema.

4 culation, and to treat the swelling disorder hereditary angioedema.

5 ms, the pathophysiology and the treatment of hereditary angioedema.

6 r C1 inhibitor (C1INH) deficiency results in hereditary angioedema.

7 enously every third day to six patients with hereditary angioedema.

8 n the prevention and treatment of attacks of hereditary angioedema.

9 occurring mutant from a patient with type II hereditary angioedema.

10 or establishing "A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency,

11 conducted in patients with acute attacks of hereditary angioedema and assessed the length of time to

12 ffective means of both preventing attacks of hereditary angioedema and treating acute attacks.

13 Hereditary angioedema attack history was collected at sc

14 ity of the pathomechanism and development of hereditary angioedema attacks in different patients.

15 HK, as was seen in plasma from patients with hereditary angioedema but not plasma from healthy subjec

16 C1INH is effective not only in patients with hereditary angioedema, but also in a variety of other di

17 ource for plasmin generation in all types of hereditary angioedema, but particularly hereditary angio

18 Because attacks of hereditary angioedema can be related to infection and/or

19 gic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency

20 Hereditary angioedema due to C1 inhibitor deficiency (HA

21 Hereditary angioedema due to C1 inhibitor deficiency is

22 the heterogeneous clinical manifestation of hereditary angioedema due to C1-INH deficiency (C1-INH-H

23 ited edematous attack (EA) in a patient with hereditary angioedema due to C1-INH deficiency to better

24 zyme systems is insufficiently controlled in hereditary angioedema due to the deficiency of C1-inhibi

25 Plasma-derived C1-INH has been used to treat hereditary angioedema for more than 30 years with excell

26 adykinin-mediated angioedema, which includes hereditary angioedema (HAE types I, II and III), acquire

27 he serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibito

28 Historically, treatment for hereditary angioedema (HAE) attacks has been administere

29 (2) receptor antagonist, in the treatment of hereditary angioedema (HAE) attacks.

30 Hereditary angioedema (HAE) caused by a deficiency of fu

31 Hereditary angioedema (HAE) caused by C1-inhibitor (C1-I

32 Recommended management of attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor

33 Hereditary angioedema (HAE) due to C1 inhibitor deficien

34 ons in Factor XII (FXII) are associated with hereditary angioedema (HAE) in the presence of normal C1

35 Hereditary angioedema (HAE) is a disease characterized b

36 Hereditary angioedema (HAE) is a heterozygous deficiency

37 Hereditary angioedema (HAE) is a rare genetic disease ch

38 Hereditary angioedema (HAE) is a rare genetic disease us

39 Hereditary angioedema (HAE) is characterized by unpredic

40 Hereditary angioedema (HAE) types I and II were then tes

41 n established treatment for acute attacks of hereditary angioedema (HAE) with C1-inhibitor (C1-INH) d

42 Hereditary angioedema (HAE) with normal C1 inhibitor (C1

43 Hereditary angioedema (HAE) with normal C1-INH (HAEnCI)

44 Deficiency of C1-INH is associated with hereditary angioedema (HAE), an autosomal inherited dise

45 Hereditary angioedema (HAE), caused by deficiency in C1-

46 d update the management and understanding of hereditary angioedema (HAE), while integrating insights

47 inhibitor under development for treatment of hereditary angioedema (HAE).

48 Hereditary angioedema is a disabling, potentially fatal

49 Hereditary angioedema is a potentially life-threatening

50 Hereditary angioedema is an autosomal-dominant deficienc

51 Hereditary angioedema is often misdiagnosed and poorly t

52 hibitor (rhC1INH) for on-demand treatment of hereditary angioedema is purified from milk of transgeni

53 In patients with hereditary angioedema, kallikrein and bradykinin formati

54 with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42

55 In subjects with hereditary angioedema, nanofiltered C1 inhibitor concent

56 t factors which trigger and/or contribute to hereditary angioedema or ACE-inhibitor-mediated angioede

57 A type I hereditary angioedema patient was recently described in

58 In the autosomal dominant disorder type I hereditary angioedema, reduced levels of C1 inhibitor ma

59 ortance of the contact activation system for hereditary angioedema-related vascular permeability.

60 Hereditary angioedema results from a congenital deficien

61 a crossover trial involving 22 subjects with hereditary angioedema that compared prophylactic twice-w

62 In patients with hereditary angioedema, the prophylactic use of a subcuta

63 Hereditary angioedema type III (HAEIII) is a rare inheri

64 MeSH terms angioedema, acquired angioedema, hereditary angioedema type III, and angiotensin converti

65 Hereditary angioedema types I and II are caused by a fun

66 Four types of acquired and three types of hereditary angioedema were identified as separate forms

67 tients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked to complete

68 terozygosity for C1INH deficiency results in hereditary angioedema, which is mediated by bradykinin.

69 us CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks i

70 Hereditary angioedema with a mutation in the PLG gene is

71 The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-I

72 Hereditary angioedema with C1 inhibitor deficiency (C1-I

73 Hereditary angioedema with C1 inhibitor deficiency is ch

74 ministration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduc

75 eight kininogen in plasma from patients with hereditary angioedema with C1 inhibitor deficiency to le

76 Patients with hereditary angioedema with C1 inhibitor deficiency were

77 the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency.

78 Hereditary angioedema with normal C1 esterase inhibitor

79 Hereditary angioedema with normal C1 inhibitor levels (H

80 s of hereditary angioedema, but particularly hereditary angioedema with normal C1 inhibitor with a fa

81 Hereditary angioedema with normal C1-INH may be linked t

82 hophysiology of the disease remains unknown (hereditary angioedema with yet unknown genetic defect [U